Tuesday, September 8, 2015
Merck, known as MSD outside the United States and Canada, and the University of Texas MD Anderson Cancer Center have entered into a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in combination with other treatments such as chemotherapy, radiation therapy and/or novel antitumor medicines.
The National Institutes of Health has announced the appointment of eight individuals to the NIH Council of Councils. The council was established to advise the NIH director on policies and activities of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), including making recommendations on research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis or would otherwise benefit from strategic planning and coordination.
VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, has initiated a pilot study to assess the feasibility of VolitionRx’s proprietary NuQ assays in detecting prostate cancer. The study is in collaboration with ImmuneHealth, a global biomarker CRO, and is taking place in Belgium.
Angle, a specialist medtech company based in England, is collaborating with the MD Anderson Cancer Center to investigate the clinical use of Angle’s Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is a center devoted exclusively to cancer patient care, research, education and prevention.